- Business Wire•6 hours ago
ARIAD Pharmaceuticals, Inc. today announced the results of clinical and translational studies on Iclusig® , its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia .
- Business Wire•yesterdayARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase inhibitor, from the ongoing Phase 1/2 and pivotal ALTA trials in patients with ALK-positive non-small cell lung cancer and intracranial central nervous system metastases.
ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance
ARIAD Pharmaceuticals, Inc. (ARIA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||13.27 x 1800|
|Ask||13.28 x 300|
|Day's Range||13.15 - 13.37|
|52 Week Range||4.37 - 14.42|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-76.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|